-
Cell: Zhou Dawang/Chen Lanfen's research group jointly published a paper revealing the important mechanism of glycogen accumulation and phase separation driving the initiation of liver cancer
Time of Update: 2021-11-03
This work found that early liver tumor cells use the extracted glucose to synthesize glycogen as energy storage, and inhibit the activity of the Hippo signaling pathway through liquid-liquid separation, thereby driving the occurrence and development of tumors .
-
Gastric Cancer TMEscore Ultimate: Combined with ICB Cohort Analysis
Time of Update: 2021-11-03
The author's analysis shows that compared with the inherent genomic characteristics of tumors, TME score can be used as a reliable biomarker for predicting ICB response in advanced gastric cancer .
-
Front Oncol: Combining PD-1 inhibitors on the basis of first-line chemotherapy can improve the prognosis of patients with advanced biliary tract cancer
Time of Update: 2021-11-03
The study retrospectively analyzed patients with advanced BTC who received PD-1 inhibitors combined with chemotherapy (anti-PD-1+C group) or chemotherapy alone (C group) in the Department of Oncology, General Hospital of the Chinese People's Liberation Army .
-
The Oncologist: The effect of the combined use of PPIs on Cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC)
Time of Update: 2021-11-03
Therefore, some foreign scholars have carried out related studies to evaluate whether the use of PPI has an impact on the efficacy, safety and residual concentration (Ctrough) of cabozantinib in mRCC patients .
-
Science fiction!
Time of Update: 2021-11-03
When the pH is less than 9, the hydrogel swelling degree is reduced, causing the fin to shrink, and it appears as a hydrogel in the microstructure.
-
Clinical Lung Cancer: The role of HER2 gene changes in EGFR mutant non-small cell lung cancer (NSCLC)
Time of Update: 2021-11-02
With the identification of various driver gene mutations, the treatment mode of advanced non-small cell lung cancer ( NSCLC ) has shifted from chemotherapy-based treatment to molecular targeted therapy-based treatment .
Breast cancerGastric Cancer FDAA total of 12,946 NSCLC patients were included in this study with analyzable EGFR and HER2 NGS data .
-
Int J Urol: The impact of platinum-based first-line chemotherapy on the overall survival of patients with metastatic urothelial carcinoma
Time of Update: 2021-11-02
Recently, researchers from Japan published an article in Int J Urol, investigating the effect of the number of cycles of chemotherapy and the objective response on the overall survival of patients with metastatic urinary tract cancer treated with pembrolizumab .
-
Cancers: Long-term efficacy and safety of neoadjuvant chemotherapy and radiotherapy in patients with early breast cancer
Time of Update: 2021-11-02
Studies have shown that neoadjuvant radiotherapy and chemotherapy for early breast cancer can achieve higher local control rates and limited adverse reactions .
Studies have shown that neoadjuvant radiotherapy and chemotherapy for early breast cancer can achieve higher local control rates and limited adverse reactions .
-
Int J Urol: A survey of predictors of survival outcomes for first-line treatment in metastatic castration-resistant prostate cancer
Time of Update: 2021-11-02
Recently, researchers from Japan published an article in "Int J Urol" to investigate the predictors of survival in patients with metastatic castration-resistant prostate cancer treated with an androgen receptor pathway inhibitor or docetaxel .
-
BMJ: Acute Urinary Retention and Occult Tumor Risk
Time of Update: 2021-11-02
The primary endpoint of the study was the subsequent risk of urogenital, colorectal, and nervous system tumors in patients with acute urinary retention compared with the general population .
Patients with acute urinary retention over 50 years of age and without obvious underlying causes should consider hidden tumor risks .
-
Eur J Cancer: Efficacy and safety of adjuvant therapy for melanoma in clinical practice: clinical research and reality
Time of Update: 2021-11-02
In Checkmate-238, compared with ipilimumab, nivolumab has a longer 12-month recurrence-free survival in patients with stage IIIB-C and IV melanoma resected .
In Checkmate-238, compared with ipilimumab, nivolumab has a longer 12-month recurrence-free survival in patients with stage IIIB-C and IV melanoma resected .
-
Cancer Commun: Clinical characteristics and prognosis analysis of Chinese KRAS mutant non-small cell lung cancer patients after chemotherapy
Time of Update: 2021-11-02
Clinical studies have shown that white patients with non-small cell lung cancer with KRAS mutations have a poor prognosis after first-line chemotherapy .
Clinical studies have shown that white patients with non-small cell lung cancer with KRAS mutations have a poor prognosis after first-line chemotherapy .
-
"Xingguang Yiyi-Deep Interpretation" online conference for the second season!
Time of Update: 2021-11-02
focuses on cellular immune therapy, working to cure cancer patients, immune June 22, 2021, Fosun Kate CAR-T cell therapy drugs Yi Kaida ® ® (A Jilun game Injection) in Officially approved in 38 countries and regions, nearly 5,000 patients have an overall response rate (ORR) of 83%, a complete response (CR) rate of 58%, and a median overall survival (OS) of 25.
-
Clin Cancer Res: The efficacy of niraparib in advanced breast cancer with BRCA1/2 germline mutations
Time of Update: 2021-11-02
The median PFS assessed locally in the Nirapali group and the PC group were 5.
9 months), the median PFS assessed by the center in the Nirapali group (n=141) was 4.
9 months), the median PFS assessed by the center in the Nirapali group (n=141) was 4.
-
Science Signaling: In vitro chemotherapy "kills" cancer cells, combined with immunotherapy to eliminate tumors without recurrence
Time of Update: 2021-11-02
immunityOn October 19, 2021, researchers from the Massachusetts Institute of Technology published a research paper entitled "The injury response to DNA damage in live tumor cells promotes antitumor immunity" in the journal " Science Signaling " .
-
science advance: Can cancer cells manipulate the nervous system?
Time of Update: 2021-11-02
Breast cancerA recent study published in Science Advances found an innovative breast cancer treatment based on analgesic nanoparticles that target the nervous system .
A recent study published in Science Advances found an innovative breast cancer treatment based on analgesic nanoparticles that target the nervous system .
-
Clin Cancer Res: Significant efficacy of reptinib in patients with advanced gastrointestinal stromal tumors with KIT/PDGFRA mutations
Time of Update: 2021-11-02
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study .
CCR-21-1864Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT / PDGFRA Mutations in the Phase III INVICTUS Study in this message
-
Nature Commnications: Ranking of the most common gene mutations in all cancers
Time of Update: 2021-11-02
This paper answers a very basic question: What are the most common mutated genes in human cancers?The research team combined gene mutation information with cancer prevalence data to reveal the genetic basis of cancer in the entire U.
-
The Oncologist: The efficacy of lenvatinib with or without everolimus (Len ± Eve) in the treatment of metastatic renal cell carcinoma (mRCC)
Time of Update: 2021-11-02
Therefore, scholars from the United States conducted a retrospective study to evaluate the progress of immune checkpoint inhibitors (ICIs) and VEGFR-TKIs combined therapy, lenvatinib combined with or without everolimus (Len ± Eve) in the treatment of metastatic kidney Efficacy of cell carcinoma (mRCC) .
-
Front Oncol: The efficacy of trastuzumab biosimilar CT-P6 in HER2-positive early stage (EBC) and metastatic breast cancer (MBC) patients in the real world
Time of Update: 2021-11-02
Recently, Korean scholars have carried out related studies to evaluate the effectiveness of CT-P6 or trastuzumab (RTZ) combined with Pertuzumab chemotherapy in the neoadjuvant treatment of her2-positive EBC patients or the palliative first-line treatment of MBC patients Sex .
